Schedule 13G ownership disclosure

Beta Bionics Inc

Common Stock · CUSIP: 08659B102

Event date: 2025-04-02

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Sands Capital Life Sciences Pulse Fund II. L.P.

    Shares: 3,154,409.00 · Class: 7.3%

  • Sands Capital Ventures, LLC

    Shares: 3,154,409.00 · Class: 7.3%

  • Frank M. Sands

    Shares: 3,154,409.00 · Class: 7.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0000904454-25-000219
Form type
SCHEDULE 13G
Filer
Beta Bionics, Inc.
CIK
CIK 1674632
Filed
Apr 09, 2025
Reporting period
Apr 02, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub